Creative Thinking Institute

The AI-native parent company behind Regenemm Healthcare.

Founded in 2019, CTI builds clinically grounded AI systems for healthcare. From early work in stress-performance monitoring, body movement analysis, biosensors, sleep, and circadian health, CTI has evolved into the parent company behind Regenemm Healthcare: a hub-and-spoke clinical AI ecosystem with a secure, consent-aware, audit-grade control plane.

About CTIExplore Regenemm

Built to make healthcare AI useful, explainable, and auditable

Creative Thinking Institute is the AI-native parent company behind Regenemm Healthcare. CTI began with the problem of human performance under stress, then expanded into physiology, sleep, circadian rhythm, wearable biosensors, soft sensing, rehabilitation movement analysis, and medical IoT data streams.

The GPT era accelerated the mission. CTI did not pivot from nothing into AI; it extended a pre-existing machine-learning, biosensor, and clinical-data thesis into AI-native healthcare infrastructure.

Choose the path that fits your work

CTI explains the research and governance layer. Regenemm shows how that work becomes clinical AI infrastructure in practice.

Clinicians and care teams

Explore how Regenemm Voice supports clinical documentation, patient summaries, handover quality and clinician-reviewed outputs.

Explore Regenemm Voice

Research and industry partners

Follow CTI's research lineage across stress-performance, biosensors, movement analysis, sleep, medical IoT and clinical AI.

View research writing

Governance and security reviewers

Review the trust posture behind Regenemm's consent-aware workflows, assurance pathway, audit evidence and security controls.

Review trust and security

Healthcare AI readers

Read current CTI essays on consent, shared transparency, interoperability, human oversight and evidence-seeking healthcare AI.

Read latest writing

What CTI contributes

CTI is the origin, governance, research, and credibility layer. Regenemm Healthcare is the platform. Shared transparency is the product.

AI-native R&D lineage

CTI's AI strategy started before the chatbot era: with structured health data, wearable signals, psychometrics, machine learning, consent, and clinical context.

Secure control plane

The Regenemm Hub governs identity, consent, audit evidence, exports, persistence, cross-spoke routing, entitlements, telemetry, and compliance evidence.

AIMS provenance

AI lifecycle controls, impact assessments, system cards, data lineage, release gates, monitoring evidence, and executive risk ownership are being built into the operating model.

Hub-and-spoke maturity

Regenemm has evolved into a hub-and-spoke architecture where domain-rich clinical workflows connect to a governed platform backbone.

Australian Government-supported R&D

Multi-year research and development discipline

Creative Thinking Institute has undertaken a multi-year research and development program for Regenemm, supported through the Australian Government's Department of Industry, Science and Resources R&D framework across 2020-2024.

This work focused on the technical challenge of combining biometric, psychometric, voice, clinical and contextual data into actionable healthcare insights. The program included experimentation in wearable data integration, real-time clinical audio processing, speaker diarisation, AI-assisted summarisation, hallucination reduction, multimodal synchronisation and clinical workflow design.

Government-supported R&D helped CTI move from biometric and psychometric health monitoring into AI-native clinical infrastructure.
Major national grant applications through programs including MRFF, AMGC and CRC sharpened CTI's evidence base, partnerships, regulatory pathway and healthcare value proposition.
Responsible AI, governed from the top

AI-native governance

Regenemm Healthcare is being built with compliance and governance embedded into its operating model. CTI works with Vanta to support its formal accreditation and assurance pathway across ISO 27001, ISO 42001, HIPAA, GDPR, and SOC 2 readiness.

The operating principle is simple: no evidence means not done. Healthcare AI must be secure, auditable, explainable, and accountable from the beginning, not retrofitted after product-market fit.

That means executive oversight, AI impact assessments, lifecycle gates, system cards, data lineage, release approvals, monitoring records, incident evidence, and Vanta-linked risk ownership.

AI-native by architecture
Hub-and-spoke design, Regenemm Voice, specialist spokes, and shared transparency across care workflows.
AI-native by workflow
Voice capture, transcription, summarisation, clinical documentation, patient-facing summaries, and care-team communication.
AI-native by governance
AIMS governance, executive oversight, lifecycle gates, risk and impact assessments, and release evidence.
AI-native by evidence
Vanta-supported ISO 27001, ISO 42001, HIPAA, GDPR, SOC 2 readiness, traceability, and audit packs.
AI-native by clinical philosophy
Clinician-in-the-loop design, patient consent, human oversight, and no autonomous clinical decision-making.
Flagship translation

Regenemm Healthcare is the platform expression of CTI's journey

Regenemm combines clinical AI assistants, structured documentation, patient-facing summaries, consent-aware workflows, interoperability, auditability, and compliance-led deployment.

AI is not a feature bolted onto the product. It is part of the clinical workflow architecture, data model, governance layer and operating system of the platform.

Regenemm Voice helps transform clinical conversations into structured documentation and patient-facing summaries designed to support clinician review, patient understanding, handover quality, and continuity of care.

Visit RegenemmTrust and security
Clinical research and ethics

Developed for clinical validation, not hype

Regenemm Healthcare is being developed with clinical research discipline, human ethics preparation and medical-device-style risk management.

The research program is designed to examine documentation efficiency, note completeness, clinician workflow, handover quality, patient communication, biosensor-assisted perioperative risk assessment and safe integration into Australian healthcare settings. AI assists with documentation and organisation of clinical information; healthcare professionals review and approve clinical content before use.

Human ethics preparation

Participant information and consent materials are being prepared around voice recording, AI processing, optional wearable data, de-identified research use and future contact.

Clinical communication platform

Regenemm is being positioned for perioperative communication workflows across surgeons, anaesthetists, nurses, perioperative physicians and documentation teams.

Medical-device-style risk

Risk management work is being developed with ISO 14971-style thinking across availability, data processing, cybersecurity, bias, drift, overreliance, training and biosensor limits.

Evidence gap

The research program targets multi-specialty perioperative documentation, Australian healthcare validation, biosensor integration and audit-grade interoperability.

Latest institute writing

Current thinking on AI in healthcare, clinical workflow, governance, and patient communication.

Stress-performance and preventative health origins
Body movement, rehabilitation, soft sensing, and biosensors
Australian Government-supported R&D across 2020-2024
Sleep, circadian health, medical IoT, and data streams
Clinical documentation and patient-facing summaries
Hub-owned distribution, entitlements, and observability
Shared transparency across clinical workflows
AIMS lifecycle gates, provenance, and human oversight
Vanta-supported ISO 27001, ISO 42001, HIPAA, and GDPR pathway
View all posts